Submitted by Anonymous (not verified) on 12 July 2024 - 16:20
Opinion/decision on a Paediatric investigation plan (PIP): Sotyktu, Deucravacitinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0250/2023
Source: